I-Mab to Participate at the H.C. Wainwright 26th Annual Global Investment Conference

ROCKVILLE, Md., Aug. 26, 2024 /PRNewswire/ -- I-Mab (NASDAQ: IMAB), a US-based, global, clinical-stage biotech company, exclusively focused on the development of highly differentiated immunotherapies for the treatment of cancer, today announced that management will present at the H.C. Wainwright 26th Annual Global Investment Conference on September 10, 2024.

H.C. Wainwright 26th Annual Global Investment Conference


            Presentation Time 
     Tuesday, September 10 at 5:00 PM ET



            Presenters          Sean Fu, PhD, Interim Chief Executive Officer (CEO)

                                 Phillip Dennis, MD, PhD, Chief Medical Officer (CMO)



            Webcast link      
     
              Here





            Meetings            One-on-one and small group meetings: September 9 -
                                  10, 2024



            Management        
     Sean Fu, PhD, Interim CEO
    Participants
                               
     Joe Skelton, Chief Financial Officer (CFO)

                               
     Phillip Dennis, MD, PhD, CMO

                                 Tyler Ehler, Senior Director, Investor Relations

The webcast will also be available under "Event Calendar" on I-Mab's IR website
at https://ir.i-mabbiopharma.com/

For more information, please contact your H.C. Wainwright representative.

About I-Mab
I-Mab (NASDAQ: IMAB) is a US-based, global, clinical-stage biotech company, exclusively focused on the development of highly differentiated immunotherapies for the treatment of cancer. I-Mab has established operations in Rockville, Maryland. For more information, please visit https://www.i-mabbiopharma.com and follow us on LinkedIn and X.

For more information, please contact:
Tyler Ehler
Senior Director, Investor Relations
IR@imabbio.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/i-mab-to-participate-at-the-hc-wainwright-26th-annual-global-investment-conference-302230144.html

SOURCE I-Mab Biopharma